---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055598"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:45:21.785626+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CytomX Q1 revenue $41.5M, up 77% YoY; positive early CX-904 data

## Summary
- Q1 revenue $41.5M vs $23.5M YoY; cash $150.3M at Mar 31, 2024.
- CX-904 (EGFRxCD3) shows favorable safety; 2 of 6 pancreatic patients with confirmed partial responses.
- CX-2051 (EpCAM ADC) first patient dosed Apr 2024; first dose cohort cleared; initial data H1 2025.
- CX-801 (IFNα2b) to start Phase 1 in Q2 2024; collaboration with Merck for KEYTRUDA combo.
- Achieved $10M in Astellas milestones for two T-cell engager programs; Dr. Zhen Su appointed to board.

## SEC filing metadata
- accession: 0000950170-24-055598
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017024055598/0000950170-24-055598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017024055598/ctmx-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055598
- JSON: https://secwatch.observer/filing/0000950170-24-055598.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055598.txt

## Key facts
- Earnings Releases
  CytomX Therapeutics, Inc. reported financial results for first quarter 2024.
  - Period: first quarter 2024
  - Result: reported results
  source text: On May 8, 2024, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000095017024055598/0000950170-24-055598-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.